Cargando…
Levetiracetam‐induced aggression and acute behavioral changes: A case report and literature review
Levetiracetam is a second‐generation antiepileptic medication used to treat a wide range of partial and generalized seizure disorders. While Levetiracetam is generally well‐tolerated, mild mood‐related side effects (e.g., anxiety, agitation, and depression) have been observed in a minority of patien...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922949/ https://www.ncbi.nlm.nih.gov/pubmed/35317062 http://dx.doi.org/10.1002/ccr3.5586 |
_version_ | 1784669596738912256 |
---|---|
author | Zhang, Jeff F Piryani, Ravi Swayampakula, Anil K Farooq, Osman |
author_facet | Zhang, Jeff F Piryani, Ravi Swayampakula, Anil K Farooq, Osman |
author_sort | Zhang, Jeff F |
collection | PubMed |
description | Levetiracetam is a second‐generation antiepileptic medication used to treat a wide range of partial and generalized seizure disorders. While Levetiracetam is generally well‐tolerated, mild mood‐related side effects (e.g., anxiety, agitation, and depression) have been observed in a minority of patients in the days following initiation of therapy or changes in dosing. The development of acute aggression requiring termination of Levetiracetam therapy has been rarely reported in the medical literature but poses a limiting effect on treatment options for refractory epilepsy in pediatric patients. In this report, we present a teenage male patient with a history of seizure disorder who developed sudden, severe behavioral abnormalities and aggression following increases in his Levetiracetam dosing. His symptoms resolved rapidly after return of his medication dosing to baseline, with no further sequelae noted. Our observations suggest that Levetiracetam remains a safe and effective first‐line antiepileptic whose adverse behavioral side effect profile can be properly managed with close patient monitoring and dose titration. |
format | Online Article Text |
id | pubmed-8922949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89229492022-03-21 Levetiracetam‐induced aggression and acute behavioral changes: A case report and literature review Zhang, Jeff F Piryani, Ravi Swayampakula, Anil K Farooq, Osman Clin Case Rep Case Reports Levetiracetam is a second‐generation antiepileptic medication used to treat a wide range of partial and generalized seizure disorders. While Levetiracetam is generally well‐tolerated, mild mood‐related side effects (e.g., anxiety, agitation, and depression) have been observed in a minority of patients in the days following initiation of therapy or changes in dosing. The development of acute aggression requiring termination of Levetiracetam therapy has been rarely reported in the medical literature but poses a limiting effect on treatment options for refractory epilepsy in pediatric patients. In this report, we present a teenage male patient with a history of seizure disorder who developed sudden, severe behavioral abnormalities and aggression following increases in his Levetiracetam dosing. His symptoms resolved rapidly after return of his medication dosing to baseline, with no further sequelae noted. Our observations suggest that Levetiracetam remains a safe and effective first‐line antiepileptic whose adverse behavioral side effect profile can be properly managed with close patient monitoring and dose titration. John Wiley and Sons Inc. 2022-03-15 /pmc/articles/PMC8922949/ /pubmed/35317062 http://dx.doi.org/10.1002/ccr3.5586 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Zhang, Jeff F Piryani, Ravi Swayampakula, Anil K Farooq, Osman Levetiracetam‐induced aggression and acute behavioral changes: A case report and literature review |
title | Levetiracetam‐induced aggression and acute behavioral changes: A case report and literature review |
title_full | Levetiracetam‐induced aggression and acute behavioral changes: A case report and literature review |
title_fullStr | Levetiracetam‐induced aggression and acute behavioral changes: A case report and literature review |
title_full_unstemmed | Levetiracetam‐induced aggression and acute behavioral changes: A case report and literature review |
title_short | Levetiracetam‐induced aggression and acute behavioral changes: A case report and literature review |
title_sort | levetiracetam‐induced aggression and acute behavioral changes: a case report and literature review |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922949/ https://www.ncbi.nlm.nih.gov/pubmed/35317062 http://dx.doi.org/10.1002/ccr3.5586 |
work_keys_str_mv | AT zhangjefff levetiracetaminducedaggressionandacutebehavioralchangesacasereportandliteraturereview AT piryaniravi levetiracetaminducedaggressionandacutebehavioralchangesacasereportandliteraturereview AT swayampakulaanilk levetiracetaminducedaggressionandacutebehavioralchangesacasereportandliteraturereview AT farooqosman levetiracetaminducedaggressionandacutebehavioralchangesacasereportandliteraturereview |